Kevin Balthaser

All filings by Kevin Balthaser on record concern Aclaris Therapeutics, Inc. The record holds 42 filings, for trades running from 1 March 2023 to 1 March 2026.

The open-market side counts 1 purchase for €70k alongside 2 sales for €22k. Taken together, the purchases exceed the sales by €48k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 17 share grants and 22 option exercises.

Most recently, on 3 March 2026, the filings show a share grant worth €1,646 in Aclaris Therapeutics, Inc. The latest purchase dates back some time: it was published 1,142 days ago, on 7 September 2023. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.